JP2017527550A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527550A5
JP2017527550A5 JP2017508482A JP2017508482A JP2017527550A5 JP 2017527550 A5 JP2017527550 A5 JP 2017527550A5 JP 2017508482 A JP2017508482 A JP 2017508482A JP 2017508482 A JP2017508482 A JP 2017508482A JP 2017527550 A5 JP2017527550 A5 JP 2017527550A5
Authority
JP
Japan
Prior art keywords
autotaxin inhibitor
inhibitor according
individual
autotaxin
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017508482A
Other languages
English (en)
Japanese (ja)
Other versions
JP6817190B2 (ja
JP2017527550A (ja
Filing date
Publication date
Priority claimed from US14/462,459 external-priority patent/US9051320B1/en
Application filed filed Critical
Publication of JP2017527550A publication Critical patent/JP2017527550A/ja
Publication of JP2017527550A5 publication Critical patent/JP2017527550A5/ja
Application granted granted Critical
Publication of JP6817190B2 publication Critical patent/JP6817190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017508482A 2014-08-18 2015-08-17 代謝障害の処置のための方法と組成物 Active JP6817190B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/462,459 2014-08-18
US14/462,459 US9051320B1 (en) 2014-08-18 2014-08-18 Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
PCT/US2015/045518 WO2016028686A1 (en) 2014-08-18 2015-08-17 Methods and compositions for the treatment of metabolic disorders

Publications (3)

Publication Number Publication Date
JP2017527550A JP2017527550A (ja) 2017-09-21
JP2017527550A5 true JP2017527550A5 (https=) 2018-09-27
JP6817190B2 JP6817190B2 (ja) 2021-01-20

Family

ID=53267810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508482A Active JP6817190B2 (ja) 2014-08-18 2015-08-17 代謝障害の処置のための方法と組成物

Country Status (4)

Country Link
US (1) US9051320B1 (https=)
EP (1) EP3183005A4 (https=)
JP (1) JP6817190B2 (https=)
WO (1) WO2016028686A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530210A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ヘテロ環式ビニルオートタキシン阻害剤化合物
US9714240B2 (en) 2013-09-17 2017-07-25 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
JP2016531874A (ja) 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
KR102515248B1 (ko) 2013-11-22 2023-03-29 사브레 테라퓨틱스 엘엘씨 오토탁신 억제제 화합물
AU2014352887A1 (en) 2013-11-22 2016-06-09 Pharmakea, Inc. Tetracyclic autotaxin inhibitors
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
US10183949B2 (en) * 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
JP6697809B2 (ja) 2015-03-06 2020-05-27 ファーマケア，インク． フッ素化リシルオキシダーゼ様２阻害剤とその使用
MX2017015225A (es) 2015-05-27 2018-02-19 Pharmakea Inc Inhibidores de la autotaxina y sus usos.
HK1253373A1 (zh) 2015-06-10 2019-06-14 Hackensack University Medical Center 使用替米沙坦预防和治疗移植物抗宿主病及其他同种免疫性和自体免疫性疾病
ES2870030T3 (es) * 2015-10-30 2021-10-26 Univ Muenster Westfaelische Wilhelms Reducción del nivel de LPA para tratar trastornos del sistema nervioso central
CA3033863C (en) * 2016-08-18 2021-09-14 Memorial Sloan Kettering Cancer Center Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema
KR102587178B1 (ko) 2016-09-07 2023-10-06 파마케아, 인크. 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법
KR102615565B1 (ko) * 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
CN106822114B (zh) * 2016-12-12 2020-08-07 中国科学院西北高原生物研究所 Mtca在制备降血糖或降血脂的药物中的用途
US11501857B2 (en) * 2018-06-14 2022-11-15 Astrazeneca Uk Limited Methods for lowering blood sugar with a metformin pharmaceutical composition
AU2019287529A1 (en) * 2018-06-14 2021-02-04 Astrazeneca Uk Limited Methods for lowering blood sugar with a gliflozin sodium-glucose cotransporter 2 inhibitor pharmaceutical composition
GR1010570B (el) 2022-12-22 2023-11-17 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης
CN116239577A (zh) * 2023-03-27 2023-06-09 沈阳药科大学 一种制备Cudetaxestat的方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210574A (en) 1991-03-08 1993-05-11 Mita Industrial Co., Ltd. Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum
US5186522A (en) 1991-09-24 1993-02-16 Midland Brake, Inc. Air dryer purge line
KR940703981A (ko) 1992-11-10 1994-12-12 존 에이취. 롱 솔레노이드 밸브 조립체(Solenoid valve assembly)
US5407368A (en) 1992-12-15 1995-04-18 Minnesota Mining And Manufacturing Company Electrode connector
US5761473A (en) 1993-01-08 1998-06-02 International Business Machines Corporation Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking
US5564949A (en) 1995-01-05 1996-10-15 Thomas & Betts Corporation Shielded compact data connector
JP2664048B2 (ja) 1995-03-27 1997-10-15 科学技術庁金属材料技術研究所長 六フッ化二ケイ素の合成法
JP4714143B2 (ja) 2004-05-19 2011-06-29 住友電気工業株式会社 Ｉｉｉ族窒化物半導体結晶の製造方法
KR101141650B1 (ko) 2004-09-30 2012-05-17 엘지전자 주식회사 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말
US20060270634A1 (en) 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
US7921385B2 (en) 2005-10-03 2011-04-05 Luminescent Technologies Inc. Mask-pattern determination using topology types
EP2170060A4 (en) 2007-06-15 2012-06-27 Univ Utah Res Found ALPHA-CHLORINE AND ALPHA-BROMPHOSPHONATE ANALOGUES OF LYSOPHOSPHATIDINIC ACID AND METHOD FOR THEIR PREPARATION AND USE
DE102007047738A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
US8268891B1 (en) 2007-11-13 2012-09-18 University Of Memphis Research Foundation Autotaxin inhibitors
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
US20110110886A1 (en) 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
WO2010040080A1 (en) 2008-10-03 2010-04-08 Abby Louise Parrill-Baker Mechanism-based inactivators of autotaxin
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
WO2010063352A1 (en) 2008-12-01 2010-06-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
MX2011010218A (es) 2009-04-02 2011-10-10 Merck Patent Gmbh Inhibidores de autotaxina.
KR20120027177A (ko) 2009-04-02 2012-03-21 메르크 파텐트 게엠베하 오토탁신 저해제로서의 피페리딘 및 피라진 유도체
BRPI1009800A2 (pt) 2009-04-02 2016-03-15 Merck Patent Gmbh compostos heterocíclicos como inibidores de autotaxina
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2763016C (en) 2009-05-20 2018-04-17 Eth Zurich Targeting micrornas for metabolic disorders
US8343934B2 (en) 2009-06-30 2013-01-01 University Of Memphis Diverse lead compound autotaxin inhibitors
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
WO2011053597A1 (en) 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
CN102822171B (zh) 2010-03-26 2015-09-02 默克专利有限公司 作为自分泌运动因子抑制剂的苯并萘啶胺类
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
US9000025B2 (en) * 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
CA2815361A1 (en) * 2010-10-20 2012-04-26 Glycomark, Inc. Improved identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2012100018A1 (en) 2011-01-20 2012-07-26 University Of Tennessee Research Foundation Inhibitors of autotaxin
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
ES2748656T3 (es) 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
IN2014DN09346A (https=) 2012-06-13 2015-07-17 Hoffmann La Roche
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
HK1212348A1 (en) 2012-12-19 2016-06-10 Novartis Ag Autotaxin inhibitors
TWI499591B (zh) 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor

Similar Documents

Publication Publication Date Title
JP2017527550A5 (https=)
Coskun et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
Camilleri et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers
Zhang et al. Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis
Seufert SGLT2 inhibitors–an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
CN120754230A (zh) 使用gip/glp1共激动剂用于治疗的方法
TW202108134A (zh) 利用達格列淨治療射血分率降低的心臟衰竭之方法
JP2017504649A5 (https=)
JP2021104999A (ja) Ｆｘｒアゴニストの新規のレジーム
TW201105336A (en) Combined medicine of pyrazole derivative and biguanide drug
Shewale et al. Azelnidipine: A Review on Therapeutic Role in Hypertension.
JP2019526644A (ja) Ｆｘｒアゴニストの組合せ
JP2013502420A5 (https=)
Jarab et al. Glycemic control and its associated factors in hypertensive patients with type 2 diabetes.
Ahrens Antibodies in metabolic diseases
Goh et al. Lower Risk of Incident Cataracts and Diabetic Retinopathy amongst Individuals Treated with Sodium Glucose Cotransporter-2 Inhibitor Compared to Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Mellitus
Johansson et al. Hyperinsulinemic rats are normotensive but sensitized to angiotensin II
Frontoni et al. Impact of drugs on diabetes risk and glycemic control
Mostafa et al. Bariatric surgery: Can it perform
Al-Rashid et al. Investigating the collective advantages of sodium-glucose cotransporter-2 inhibitors and GLP-1 analogs in addressing metabolic health issues linked to obese type 2 diabetes mellitus and related comorbidities
Ryan Increased risk for type 2 diabetes mellitus with HIV-1 infection
Zeng et al. imidazole propionate: an emerging target for the
Lian et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease: Unraveling Connections and Advancing Therapies
Hopper et al. Treating comorbidities in heart failure: tackling the hidden burden
Greenwood et al. WCN24-1556 The clinical and health economic effect of a 6-month physical activity digital health intervention on health-related quality of life in people with chronic kidney disease